Molecular Nutrition & Food Research · 2016 · 35 citations · 36 references
MedicineGeneticsPharmacologyBone MetabolismHuman GeneticsMedical GeneticsBone HealthBone Metabolism DisordersDown SyndromeGenetic DisordersGenetic SyndromesMetabolic Bone DiseaseBone Mineral HomeostasisNutritional Effects On BonePolyphenol ContentSkeletal AbnormalitiesSkeletal Developmental DefectsSkeletal ModificationVitamin Supplements
SCOPE: Down syndrome (DS), caused by trisomy of human chromosome 21 (Hsa21), is characterized by a spectrum of phenotypes including skeletal abnormalities. The Ts65Dn DS mouse model exhibits similar skeletal phenotypes as humans with DS. DYRK1A, a kinase encoded on Hsa21, has been linked to deficiencies in bone homeostasis in DS mice and individuals with DS. Treatment with Epigallocatechin-3-gallate (EGCG), a known inhibitor of Dyrk1a, improves some skeletal abnormalities associated with DS in mice. EGCG supplements are widely available but the effectiveness of different EGCG-containing supplements has not been well studied. METHODS AND RESULTS: Six commercially available supplements containing EGCG were analyzed, and two of these supplements were compared with pure EGCG for their impact on skeletal deficits in a DS mouse model. The results demonstrate differential effects of commercial supplements on correcting skeletal abnormalities in Ts65Dn mice. Different EGCG-containing supplements display differences in degradation, polyphenol content, and effects on trisomic bone. CONCLUSION: This work suggests that the dose of EGCG and composition of EGCG-containing supplements may be important in correcting skeletal deficits associated with DS. Careful analyses of these parameters may lead to a better understanding of how to improve skeletal and other deficits that impair individuals with DS.
36
Samantha E. Parker, Mark A. Canfield, Russel Rickard et al. · Birth Defects Research Part A Clinical and Molecular Teratology · 2010 · 1.9K citations
Public Health, Maternal Health, Population Health Sciences +16
The specificities of protein kinase inhibitors: an update
Jenny Bain, Hilary McLauchlan, Matthew Elliott et al. · Biochemical Journal · 2003 · 1.4K citations · Full text
A mouse model for Down syndrome exhibits learning and behaviour deficits
Roger H. Reeves, Nicholas G. Irving, Timothy H. Moran et al. · Nature Genetics · 1995 · 914 citations
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21
Joseph R. Arron, Monte M. Winslow, Alberto Polleri et al. · Nature · 2006 · 698 citations